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Abstract 15 
 16 
Background. Inherited renal disorders comprise a significant proportion of cases in both 17 
paediatric and adult nephrology services. Genetic advances have advanced rapidly whilst 18 
clinical models of care delivery have remained static.  19 
Aim. To describe a cohort of patients attending a multidisciplinary renal genetics clinic and 20 
the insights gained from this experience. 21 
Design and Methods. A retrospective review of clinic cases and their molecular genetic 22 
diagnosis over a five year period. 23 
Results. We report details of 244 individuals including 80 probands who attended the clinic. 24 
The commonest reasons for referral was familial haematuria which accounted for 37.5% of 25 
cases and cystic kidney disease, accounting for 31% of cases. 18 probands had a known 26 
molecular genetic diagnosis and were referred for genetic counselling and screening of at risk 27 
relatives and management plans. 62 probands and their families were referred for a precise 28 
molecular diagnosis and this was achieved in 26 cases (42%). The most frequent new genetic 29 
diagnoses were COL4A5 mutations underlying familial haematuria and familial end stage renal 30 
disease. The clinic also allowed for patients with rare renal syndromes to be reviewed, such as 31 
ciliopathy syndromes, allowing detailed phenotyping and often a precise molecular genetic 32 
diagnosis to be provided.  33 
Conclusions. The integration of modern day genetics and genomics into multidisciplinary 1 
clinics often allows a precise diagnosis which benefits patients, their relatives and the clinicians 2 
providing care and future management. 3 
  4 
Introduction 1 
 2 
Inherited renal diseases are a significant cause of chronic kidney disease (CKD) and end stage 3 
renal disease (ESRD) in both adult and paediatric populations. The causes of ESRD in children 4 
include renal tract malformations in around 35% of cases 1, congenital nephrotic syndrome in 5 
10% and cystic kidney disease in 5%. It is becoming clearer that variants in genes encoding 6 
transcription factors important for renal development (and maintenance) such as WT1, PAX2 7 
and HNF1B may lead to both renal tract malformations and renal syndromes with significant 8 
extra-renal features 2, 3. Genetic renal tract disorders also contribute to a significant (and 9 
probably under-diagnosed) proportion of later-onset (adult) ESRD. Awareness and recognition 10 
of inherited renal disorders and the documentation of detailed family history are vital factors 11 
to ensure a genetic diagnosis is not missed 4.  Within reported cohorts of adults with kidney 12 
disease, autosomal dominant polycystic kidney disease (ADPKD) is the commonest 13 
monogenic genetic cause 5,6, accounting for ~10% of ESRD in the UK 7 whilst other forms of 14 
cystic kidney disease are rare. Inherited collagenopathies, including Alport syndrome, are 15 
being increasingly recognised as a cause of adult onset kidney disease. Mutations in the COL4 16 
genes account for Alport syndrome and familial haematuria syndromes and are one of the 17 
commonest causes of familial focal segmental glomerulosclerosis (FGSG) 8.  18 
 19 
Timely and early recognition, diagnosis and management of these forms of kidney disease is 20 
therefore extremely important. Through a close working relationship between clinical genetics 21 
and both adult and paediatric nephrology we have developed a multidisciplinary renal genetics 22 
clinic for families and patients in whom a genetic renal disorder was suspected. Here we report 23 
a five-year review of the case load, as part of a registered audit adhering to local guidelines and 24 
discuss clinical benefits and impact of this multi-specialty clinic, based in the north east of 25 
England. 26 
 27 
 28 
 29 
Results   30 
 31 
In 2007 a multidisciplinary renal genetics clinic was established within the Renal Services 32 
Department, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust. Our 33 
aim was to provide genetic diagnosis to guide management, screening and counselling of 34 
families with inherited renal disorders in response to a clinical need. The multidisciplinary 1 
clinic design allowed a clinical geneticist, an adult nephrologist (with a special interest in renal 2 
genetics) and a paediatric nephrologist to see families together within the same clinic room. 3 
We hosted the clinic every 3 months. Genetic testing was performed largely using targeted 4 
single gene tests and small panels available through the UK Genetic Testing Network 5 
(UKGTN,  http://ukgtn.nhs.uk/), with occasional testing undertaken in a research basis. 6 
Typically, probands and their family members were seen just once within this multidisciplinary 7 
setting and appropriate follow up with individual clinicians was arranged for subsequent visits. 8 
 9 
From 2007-2011 a total of 244 individuals, comprising 80 probands, 50 affected relatives and 10 
114 unaffected relatives were reviewed within this multidisciplinary clinic. The number of 11 
family members ranged from 1 to 7 members in total, with a mean of ~3. The mean age of the 12 
probands at time of referral was ~19 years. Ages ranged from new-born children to adults 57 13 
years of age. 50 probands (62.5%) were less than 18 years of age at their clinic review. The 14 
vast majority of probands were white Europeans, with no known consanguinity, with only 6 15 
probands of Asian origin, two of whom were from consanguineous families. 16 
 17 
Referrals were mostly from paediatric nephrology services, accounting for 56 of the 80 18 
probands, with the remainder from adult nephrology (14) clinical genetics (3), primary care 19 
(4), surgery (2) and oncology (1). The clinic was designed to be a tertiary referral centre and 20 
attracted patient referrals from the whole of the north of England. Patients attended from as far 21 
as Scarborough (99 miles) and Cumbria (98 miles). The mean distance of travel to the clinic 22 
for each family who attended was 22 miles. 23 
 24 
The most common reasons for referral were for investigation of a suspected familial haematuria 25 
(often with proteinuria and associated with CKD and ESRD) or for investigation and diagnosis 26 
of a possible inherited cystic kidney disease (Table 1). 18 of the probands had a known genetic 27 
diagnosis with pathogenic or likely pathogenic mutations prior to referral (Table 2). These 28 
patients and their families were referred for genetic counselling and information prior to 29 
clinical, biochemical and genetic screening as well as disease management and prognosis in 30 
light of genetic results. The remaining 62 probands had an unknown or imprecise clinical 31 
diagnosis and were referred to clarify both a clinical and molecular genetic diagnosis. 32 
 33 
 34 
Of the 62 cases referred for a more precise molecular genetic diagnosis, this was provided in 1 
26 cases (42%). Molecular genetic diagnoses made following the clinic (Table 3) included 2 
COL4 associated disease in 16 probands. There were no common or founder mutations 3 
identified within this cohort, which was perhaps unexpected in this very stable population. In 4 
almost every case genetic testing identified pathogenic changes that had been previously 5 
reported or novel changes with predicted pathogenicity. In one proband molecular testing 6 
identified a COL4A5 variant of uncertain significance. Here segregation of the variant was 7 
performed to allow clinical phenotypes to be correlated with this genotype. RNA studies were 8 
not routinely carried out but we anticipate, with wider genetic testing (using panels, whole 9 
exome and whole genome approaches) such additional studies will be required to confirm 10 
pathogenicity of splice-site mutations and other intronic changes predicted to affect splicing.   11 
 12 
Nine probands remained without a molecular diagnosis, despite targeted genetic testing of 13 
candidate genes available through UKGTN at the time. These cases included familial 14 
haematuria (4), congenital anomalies of the kidney and urinary tract (CAKUT) (1), renal cystic 15 
disease (2), early onset hypertension (1) and a suspected ciliopathy (1). Several of these 16 
probands and their relatives who remained genetically unsolved, were subsequently recruited 17 
to the Newcastle pilot study of the Genomics England 100,000 Genomes Project 18 
(https://www.genomicsengland.co.uk/) for more detailed genetic studies. 19 
 20 
 21 
 22 
Novel insights from the clinic  23 
 24 
 25 
The combined family clinic was a valuable setting in which to take time to explore renal and 26 
extra renal phenotypes and to consider rare diagnoses. Excluding cases of ADPKD, which is 27 
commonly associated with the extra renal manifestation of liver cysts, there were extra renal 28 
manifestations present in 25 of the cases, pointing to rare syndromes. These included deafness 29 
(in 6 probands), gout, liver fibrosis, skeletal abnormalities and retinal defects.  One family, 30 
which we have previously reported 9, presented with an autosomal dominant pattern of 31 
progressive renal failure comprising renal dysplasia (CAKUT) and a history of eye disease. A 32 
renal coloboma syndrome was suspected. Ophthalmological examination revealed optic nerve 33 
colobomas and mutation analysis subsequently confirmed PAX2 mutations segregating with 34 
renal and eye phenotypes.  Establishing a genetic diagnosis within this family helped to identify 1 
other at risk family members who could be screened for mutations. Those who were mutation 2 
positive could be investigated appropriately with renal and ophthalmological testing, but 3 
avoiding invasive tests such as renal biopsies. It is worth noting that the complications of renal 4 
biopsy may be serious and include bleeding requiring transfusion (0.9%), angiographic 5 
intervention (0.6%) and rarely nephrectomy (0.01%) 10. The risk of fatality following renal 6 
biopsy is small (0.02%) but real 10. 7 
 8 
In another family, we were able to diagnose CEP290 mutations as a cause of a retinal-renal-9 
cerebellar syndrome (Joubert syndrome) who presented with visual loss, cystic kidney disease 10 
and rapidly declining renal function. Establishment of a precise diagnosis allowed focused 11 
investigations, avoided renal biopsy and allowed decision making on family planning and renal 12 
transplantation.  13 
 14 
The diagnosis of a truncating PKD1 mutation was made in one family whose child presented 15 
with a febrile illness at 8 weeks of age prompting a renal USS, which was diagnostic for 16 
ADPKD. However, both parental renal USS were normal, suggesting a de novo mutation in 17 
this family, which was confirmed on molecular genetic testing. The importance of a precise 18 
diagnosis of inherited cystic kidney disease cannot be emphasized enough. Autosomal 19 
dominant polycystic kidney disease (ADPKD) is common, and should be easily recognised 11. 20 
However, in around 1% of cases it may present with cystic kidney disease at birth and the 21 
diagnosis may be confused with other congenital cystic diseases. Typical extra renal features 22 
of ADPKD include liver cysts and intracranial aneurysm formation. ADPKD does however 23 
have its mimics and mutations in HNF1B, OFD1 and TSC1/2 can phenocopy the cystic kidney 24 
disease phenotype 12. In this cohort we did not routinely screen for PKD1 and PKD2 mutations 25 
in cases of cystic kidney disease but reserved these tests where there was true diagnostic 26 
uncertainty or a pressing clinical need, such as very early onset disease or a molecular diagnosis 27 
was essential for reproductive decisions, in accordance with UKGTN guidelines. We made a 28 
new molecular genetic diagnosis of PKD1 mutation in 4 families, 2 of whom the proband were 29 
paediatric presentations of cysts. In each of these families, this molecular diagnosis has allowed 30 
other family members considering live-donor kidney transplantation to be genetically screened. 31 
Recent increased availability of such genetic tests will allow these tests to be undertaken more 32 
readily to allow a precise diagnosis, which is often needed for planning live-related kidney 33 
transplantation, as an ultrasound diagnosis of ADPKD can be imprecise below the age of 40 34 
years of age. An early (childhood) diagnosis of ADPKD may allow the detection and treatment 1 
of hypertension and the early use of disease modifying drugs (within clinical trials) such as 2 
tolvaptan. 3 
 4 
The most frequent reason for referral was suspected familial haematuria and the most common 5 
molecular diagnosis of COL4 mutations reflected this. We identified families with X-linked, 6 
autosomal dominant and autosomal recessive COL4 disease. An extended pedigree diagram 7 
which included the presence of deafness, haematuria, proteinuria and ESRD helped to 8 
determine the likely pattern of inheritance, which was then confirmed at the molecular genetic 9 
basis. Patients with suspected COL4 mutations were sent for formal audiology and 10 
ophthalmological examinations.  11 
 12 
The Newcastle clinic is not unique in the UK. A similar model in London, with an emphasis 13 
on paediatric renal malformations has been previously reported  13. There are also 14 
multidisciplinary renal genetics clinics in Cambridge and Manchester. The emphasis on a 15 
genetic diagnosis and appropriate counselling, investigation and treatment of families in a 16 
multidisciplinary setting is a shared aim. Various combinations of consultants in nephrology, 17 
paediatrics, genetics and urology can be brought together to provide an environment of 18 
excellence to allow rare renal diseases to be managed appropriately. A multidisciplinary renal 19 
genetics clinic experience has been recently reported from Australia 14 where molecular genetic 20 
testing confirmed a diagnosis in about half the cohort and allowed a change in diagnosis in a 21 
around a quarter of the referred cases. Multidisciplinary genetics clinics are applicable to many 22 
medical specialities and in our view will be increasingly required to bridge between advances 23 
in genetics and genomics and clinical medicine to allow the diagnosis and management of 24 
inherited disease. 25 
 26 
Our clinic experience has helped us to identify certain take away messages. These include the 27 
ability to, when seeing whole families together, identify variable phenotypes and incomplete 28 
penetrance within families. This observed variability illustrates the complexities of monogenic 29 
inherited diseases and the intricacies of genetic counselling and predicting long term prognosis 30 
for patients with risk alleles. There is also a holistic benefit of seeing family members together. 31 
Advice and management plans can be given to the whole family, avoiding the mixed messages 32 
that family members may receive when seeing different medical professionals in isolation. This 33 
also facilitates a provision of balanced and consistent advice to the referring physician and the 1 
primary care physician which can be executed locally, as required.  2 
 3 
We also observed a broadening of previously described phenotypes, this was especially true 4 
for patients with ciliopathy syndromes.  A clear advantage of the clinic was the ability to collect 5 
accurate phenotypic information at the same time as collecting DNA samples in multiple 6 
family members to allow testing of the most appropriate / informative individual and then allow 7 
cascade screening to proceed in an effective manner. This approach also allows variants of 8 
uncertain significance identified in a proband to be tested for segregation with disease 9 
phenotypes in other family members.  10 
 11 
We have also valued the opportunity to discuss novel therapies (often with the emphasis on 12 
personalised medicine approaches) with families and involve them in active research projects 13 
and rare disease programmes (such as The National Registry of Rare Renal Disease (RaDaR) 14 
www.rarerenal.org).  15 
 16 
The cost of genetic testing is an important consideration for any genetics clinic. 17 
Multidisciplinary clinics in themselves are costly, without the addition of expensive genetic 18 
tests. In the UK, costs of individual gene tests do remain disproportionately high compared to 19 
large panel and whole exome sequencing approaches. Whole genome sequencing with virtual 20 
gene panels to allow filtering of sets of genes to certain phenotypes will hopefully become part 21 
of routine NHS care in the UK following the vision of Genomic England’s 100,000 Genomes 22 
Project. The integration of lessons learnt from such approaches with UKGTN’s expanding 23 
portfolio will hopefully allow a more cost effective diagnostic genetic service to be developed. 24 
The economic case for performing a panel gene test, whole exome or even whole genome 25 
sequencing test in patients with rare disease and undiagnosed disease should now be easily 26 
accepted 15. Cost effectiveness analysis data from diagnostic genetic clinics has recently been 27 
reported 16, 17.  Before a genetic diagnosis patients are often seen by multiple clinicians and 28 
have multiple expensive and often invasive investigations. As an example, the cost of 29 
performing a gene panel test for familial haematuria in a proband and the additional cost for 30 
screening of variants in at risk family members can be offset against multiple investigations 31 
that may be carried out among multiple members of the same family. Tests such as cystoscopies 32 
and renal biopsies are frequently performed in order to secure a diagnosis, often without any 33 
co-ordination between family members or their clinicians. 34 
 1 
The power of securing a molecular genetic diagnosis in a large family of affected patients and 2 
at risk relatives reduces the need for invasive, costly and often unnecessary investigations (such 3 
as percutaneous renal biopsy and cystoscopy) in multiple relatives. These clinical and 4 
radiological investigations, as well as being expensive, can be stressful, given their lack of 5 
diagnostic precision. 6 
 7 
 8 
Conclusions 9 
 10 
The power of a precise diagnosis is increasingly important, valued and achievable. Families 11 
have often seen many doctors and specialists and have not been offered a unifying diagnosis. 12 
There is a palpable and real benefit for both the patients and their physicians in securing a 13 
molecular genetic diagnosis. There is almost certainly a health economic value of ending the 14 
diagnostic odyssey for patients with genetic and often rare disease. It allows, within the clinic 15 
or follow up clinics, an opportunity to explain mechanisms of disease, explain risks of 16 
progression of renal disease and risk of extra renal manifestations. Lifestyle changes can be 17 
made with more positivity once a firm diagnosis is established. A precise diagnosis in a 18 
paediatric nephrology patient will hopefully ensure a more planned transition into adult 19 
nephrology services.  The long term study of cohorts of patients with inherited disease will 20 
allow clinicians to learn more about disease progression and outcomes, which in turn will help 21 
families who are desperate to learn more about the implications of their inherited disease. 22 
Furthermore, having a precise genetic diagnosis allows the identification of at risk relatives 23 
and contributes in family planning decisions through assisted reproductive medicine. The 24 
multidisciplinary approach maximizes the use of time for the patients and the physicians. The 25 
future vision, which has been cast by Genomics England is to allow genomic medicine to 26 
permeate throughout the NHS to allow efficient and precise molecular diagnoses to inform 27 
clinical care. Such genomic medicine programs are not without their obstacles but the benefits 28 
may be huge 18. Certainly a move away from individual gene tests to panel, exome and genome 29 
approaches will allow a more thorough and cost effective genetic analysis, and the UKGTN’s 30 
expanding portfolio (http://ukgtn.nhs.uk/) confirms the utility of such approaches. Genetic 31 
testing alone is meaningless without precise phenotyping data and the ability of astute 32 
clinicians to provide this should never be disregarded. We firmly believe our multidisciplinary 33 
approach to renal genetic provides added value and improves patient diagnosis and care. 34 
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Table 1: Clinical features and reason for referral 2 
 3 
Familial haematuria 30 (37.5%) 
Cystic kidney disease 25 (31.3%) 
Congenital abnormality of kidney / urinary tract 
(CAKUT) 
7 (8.8%) 
Tubulopathy / electrolyte disturbance 7 (8.8%) 
Ciliopathy syndrome 4 (5%) 
Tuberose sclerosis complex (TSC) 3 (3.8%) 
Congenital nephrotic syndrome 2 (2.5%) 
Early onset hypertension 2 (2.5%) 
 4 
  5 
 1 
Table 2: Known molecular genetic diagnosis prior to clinic 2 
 3 
Clinical Diagnosis 
Gene 
Number of 
probands 
Diabetes insipidus AVPR2 3 
Joubert syndrome  C5ORF42 1 
Joubert syndrome with nephronophthisis CEP290 1 
Autosomal dominant Alport syndrome COL4A3 1 
X-linked Alport syndrome COL4A5 1 
Renal cysts and diabetes syndrome 
(RCAD) 
HNF1B 1 
Donnai-Barrow syndrome LRP2 1 
Autosomal Dominant Tubulointerstitial 
Kidney Disease (ADTKD) 
MUC1 1 
Oro-facial-digital syndrome OFD1 1 
Autosomal recessive polycystic kidney 
disease (ARPKD) 
PKHD1 1 
Autosomal Dominant Tubulointerstitial 
Kidney Disease (ADTKD) 
REN 1 
Autosomal Dominant Tubulointerstitial 
Kidney Disease (ADTKD) 
UMOD 5 
 4 
 5 
  6 
 1 
Table 3: Confirmed clinical and molecular diagnoses made following a clinic visit 2 
 3 
Reason for Referral Clinical Diagnosis Gene Number of 
probands 
confirmed 
Suspected ciliopathy 
syndrome 
Joubert syndrome CC2D2A 1 
Suspected ciliopathy 
syndrome 
Joubert syndrome CEP290 1 
Tubulopathy Bartter’s syndrome CLCNKB 1 
Familial haematuria Autosomal 
dominant Alport 
syndrome / Thin 
basement 
membrane 
nephropathy 
COL4A3 3 
Familial haematuria Autosomal 
dominant Alport 
syndrome / Thin 
basement 
membrane 
nephropathy 
COL4A4 4 
Familial haematuria X-linked Alport 
syndrome 
COL4A5 9* 
Congenital nephrotic 
syndrome 
Congenital 
Nephrotic 
syndrome 
NPHS1 1 
CAKUT Renal coloboma 
syndrome 
PAX2 1 
Cystic kidney disease Autosomal 
dominant 
PKD1 4 
polycystic kidney 
disease 
Tubulopathy Hypomagnesemia 
with secondary 
hypocalcemia 
TRPM6 1 
 1 
*Includes one proband with a VUS (which segregated with phenotype) in COL4A5 2 
 3 
 4 
 5 
 6 
